Clinical Characteristics of Adenosquamous Carcinoma of the Pancreas A Matched Case-Control Study

被引：47

作者：

Imaoka, Hiroshi ^{[1
]}

Shimizu, Yasuhiro ^{[2
]}

Mizuno, Nobumasa ^{[1
]}

Hara, Kazuo ^{[1
]}

Hijioka, Susumu ^{[1
]}

Tajika, Masahiro ^{[1
]}

Kondo, Shinya ^{[1
]}

Tanaka, Tsutomu ^{[1
]}

Ogura, Takeshi ^{[1
]}

Obayashi, Tomohiko ^{[1
]}

Hasegawa, Toshiyuki ^{[3
]}

Niwa, Yasumasa ^{[1
]}

Yamao, Kenji ^{[1
]}

机构：

[1] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi 4648681, Japan

[2] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Nagoya, Aichi 4648681, Japan

[3] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan

来源：

PANCREAS | 2014年 / 43卷 / 02期

关键词：

pancreatic cancer; endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA); adenosquamous carcinoma of the pancreas (ASC); pancreatic ductal adenocarcinoma (PDAC); matched case-control study; DIFFERENTIATION; ENDOCRINE; GEMCITABINE;

D O I：

10.1097/MPA.0000000000000089

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objectives Adenosquamous carcinoma of the pancreas (ASC) is a variant of pancreatic ductal adenocarcinoma (PDAC), but the prognosis remains unclear. The purpose of this study was to clarify the prognosis of ASC using a matched case-control design. Methods We evaluated clinical characteristics of ASC treated between 2001 and 2011 in our institution. As controls, PDAC cases matched with ASC cases for sex, age, pretreatment Eastern Cooperative Oncology Group performance status, location, initial therapy and American Joint Committee on Cancer TNM staging for pancreatic cancer were also evaluated. Results Of the 914 cases of pancreatic neoplasm, 28 cases (3.06%) of ASC were identified, and 56 cases of PDAC were matched as controls. Median overall survival (OS) was significantly worse for ASC (8.38 months) than for PDAC (15.75 months; hazard ratio [HR], 1.94; 95% confidence interval, 1.07-3.51; P = 0.026). Of the 22 unresected cases, median OS was again significantly worse for ASC (4.67 months) than for PDAC (12.36 months; HR, 2.39; 95% confidence interval, 1.27-4.51; P = 0.007). Conclusion These results demonstrate that ASC is more aggressive than PDAC.

引用

页码：287 / 290

页数：4

共 26 条

[1]

[Anonymous], 2000, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System

[2] 415 Patients with Adenosquamous Carcinoma of the Pancreas: A Population-Based Analysis of Prognosis and Survival [J].

Boyd, Casey A. ;

Benarroch-Gampel, Jaime ;

Sheffield, Kristin M. ;

Cooksley, Catherine D. ;

Riall, Taylor S. .

JOURNAL OF SURGICAL RESEARCH, 2012, 174 (01) :12-19

[3] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[4]

Herxheimer G, 1907, BEITR PATHOL ANAT AL, V41, P348

[5]

Hruban R H., 2007, Tumors of the Pancreas (AFIP Atlas of Tumor Pathology Series 4, Fascicle 6)

[6] Adenosquamous carcinoma of the pancreas [J].

Hsu, JT ;

Yeh, CN ;

Chen, YR ;

Chen, HM ;

Hwang, TL ;

Jan, YY ;

Chen, MF .

DIGESTION, 2005, 72 (2-3) :104-108

[7]

ISHIKAWA O, 1980, CANCER-AM CANCER SOC, V46, P1192, DOI 10.1002/1097-0142(19800901)46:5<1192::AID-CNCR2820460519>3.0.CO

[8]

2-D

[9] Squamous Cell Carcinoma of the Pancreas [J].

Itani K.M.F. ;

Karni A. ;

Green L. .

Journal of Gastrointestinal Surgery, 1999, 3 (5) :512-515

[10] Adenosquamous carcinoma of the pancreas: A clinicopathologic series of 25 cases [J].

Kardon, DE ;

Thompson, LDR ;

Przygodzki, RM ;

Heffess, CS .

MODERN PATHOLOGY, 2001, 14 (05) :443-451

← 1 2 3 →